CytoDyn Inc.
CYDY
Rank in Stocks
#14290
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical... CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab β an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Share Price
$0.24
Last synced: 2026-11-12
Market Cap
$331.73M
Change (1 day)
3.49%
Change (1 year)
-9.43%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CytoDyn Inc. (CYDY)
Category
Healthcare
EPS for CytoDyn Inc. (CYDY)
EPS as of August 2026 TTM: $-0.04
According to CytoDyn Inc.'s latest financial reports, its current EPS (TTM) is $-0.04. At the end of 2025 the company had an EPS of 0.00, an increase over its 2024 EPS of $-0.05.
EPS history for CytoDyn Inc. from 2004 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.04 | -103.59% |
| 2025 | 0.00 | -103.59% |
| 2024 | $-0.05 | -44.55% |
| 2023 | $-0.10 | -77.81% |
| 2022 | $-0.43 | 43.33% |
| 2021 | $-0.30 | -11.76% |
| 2020 | $-0.34 | 61.90% |
| 2019 | $-0.21 | -25.00% |
| 2018 | $-0.28 | 47.37% |
| 2017 | $-0.19 | -29.63% |
| 2016 | $-0.27 | -38.64% |
| 2015 | $-0.44 | 62.96% |
| 2014 | $-0.27 | -15.63% |
| 2013 | $-0.32 | 6.67% |
| 2012 | $-0.30 | 66.67% |
| 2011 | $-0.18 | -10.00% |
| 2010 | $-0.20 | 81.82% |
| 2009 | $-0.11 | 0.00% |
| 2008 | $-0.11 | -54.17% |
| 2007 | $-0.24 | 41.18% |
| 2006 | $-0.17 | 41.67% |
| 2005 | $-0.12 | 120.18% |
| 2004 | $-0.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.99 | 2,134.76% |
US
|
|
| $15.66 | -35,449.89% |
US
|
|
| $-7.07 | 15,859.37% |
US
|
|
| $-5.29 | 11,841.31% |
AU
|
|
| $12.88 | -29,174.72% |
BE
|
Questions about CytoDyn Inc.'s earnings per share (EPS)
What is CytoDyn Inc.'s earnings per share (EPS)?
CytoDyn Inc.'s earnings per share (EPS) over the last twelve months is $-0.04, as of Aug 2026.
What was CytoDyn Inc.'s earnings per share (EPS) in 2025?
In 2025, CytoDyn Inc.'s earnings per share (EPS) was 0.00, compared with $-0.05 in 2024.
How has CytoDyn Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, CytoDyn Inc.'s earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2022 ($-0.43).
How does CytoDyn Inc.'s earnings per share (EPS) compare with similar companies?
CytoDyn Inc.'s earnings per share (EPS) ($-0.04) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.